WeVote
Log In

Bill

Bill

HR 290

HEALTH: Requests the Louisiana Department of Health to study the effects of gender affirming therapy on mental health

2026 Regular Session Introduced by Jessica Domangue

Louisiana LDH is asked to study whether gender-affirming hormone therapies are linked to psychosis and related psychiatric conditions in people 26 or younger, and report by Feb 1,

Read by title, under the rules, referred to the Committee on Health and Welfare.
0
WeVote Research Nonpartisan
Bill Summary · HR 290

Overview

  • Bill: HR 290
  • Session: 2026 Regular Session
  • Jurisdiction: Louisiana
  • Committee/Referral: House of Representatives (Health and Welfare, per standard process)
  • Author/Co-sponsor: Prime sponsor Representative Domangue; Co-sponsor Rep. Jessica Domangue
  • Type: Concurrent resolution urging an executive agency to study a public health issue

Purpose and intent

  • The resolution urges the Louisiana Department of Health (LDH) to study the potential correlation between medications used in gender-affirming hormone therapy and the incidence of psychosis and related psychiatric conditions in individuals aged 26 years and younger.
  • The objective is to provide findings and recommendations to the Legislature via a written report.

Key provisions and scope

  • The LDH is requested to conduct a study in consultation with qualified medical professionals, researchers, and mental health experts.
  • The study should address, at minimum: 1) A review of available peer-reviewed medical and scientific literature on psychiatric outcomes associated with:
    • Estrogen and testosterone therapies
    • Androgen blockers
    • Puberty blockers
    • Cross-sex hormones
    • Related medications 2) Examination of adverse event data (where available) related to psychosis, schizophrenia-spectrum disorders, severe mood disorders, dissociative conditions, suicidal ideation, and other significant psychiatric symptoms. 3) Consultation with a broad range of healthcare professionals, including behavioral health specialists, endocrinologists, obstetrician-gynecologists, psychiatrists, therapists, pediatric specialists, pharmacologists, and other qualified experts representing diverse medical perspectives. 4) Potential recommendations on:
    • Informed consent standards
    • Patient screening practices
    • Mental health evaluations
    • Monitoring protocols
    • Areas requiring additional research
  • Deliverable: A written report detailing findings and, if warranted, recommendations.

Timeline and procedural aspects

  • Reporting deadline: No later than February 1, 2027.
  • Submission: The LDH is to provide the report to the Louisiana House Committee on Health and Welfare.
  • Status note: As of the bill’s introduction, the action listed is a request; no binding mandate on LDH beyond producing a report.

Who/what is affected

  • Primary entity: Louisiana Department of Health (LDH) and its capacity to convene expert consultation and compile data.
  • Population focus: Individuals 26 years old and younger who may be receiving gender-affirming hormone therapy.
  • Indirect effects: Healthcare professionals, patients, families, and policymakers who rely on LDH findings to inform clinical guidelines, consent practices, and monitoring protocols.

Context and potential impact

  • The resolution aims to inform policy discussions by synthesizing existing literature and data regarding possible psychiatric outcomes related to gender-affirming therapies in a younger population.
  • Outcomes could influence state-level considerations of informed consent standards, screening, monitoring, and future research priorities.
  • It does not mandate changes to clinical practice or funding, but it could shape legislative and regulatory discourse if findings identify notable associations or gaps in evidence.

Summary

HR 290 is a non-binding resolution that directs the Louisiana Department of Health to undertake a focused review of scientific literature, data, and expert input on whether medications used in gender-affirming hormone therapy are associated with psychosis and related psychiatric conditions in individuals 26 and under. The LDH should deliver a comprehensive report, including any recommendations on consent, screening, monitoring, and areas needing further research, to the House Committee on Health and Welfare by February 1, 2027.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.